COILED THERAPEUTICS PLC (COIL) — Interim Results

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Rockford Therapeutics PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish a response where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Executive Chairman, Stephen West. Good morning, sir. Great. Thanks, Lily, and good morning, everyone. My name is Steve West. I'm the Chairman of Rockford Therapeutics. I'm joined here today by Adjane Reginald, who is our CEO. And we're here to talk about our interim results, which we released this morning, and also to give you a brief company update as well. So without much further ado, I'll jump into the presentation. Disclaimer. So just to remind everyone who we are. We are a listed biotech company. We're focused on developing first in class medicines in the high value and high growth oncology market prior to partnering or selling to big pharma. That really does explain what why we're here, what we're doing, and I hope you can see that we've achieved a lot in this space in the last six months of this year as well. So moving on to the interim results. So just a few highlights here. So cash at bank end of June was 1,380,000. We had a net loss for the six months of 742,000, which compared reasonably favorably with the previous six months of previous interims of 22. Loss per share has come down dramatically. Our total assets have gone up, ...